title: Clinical commentary: Medical ethics and the ramifications of equipoise in clinical research. Is a confirmatory trial using a non-bevacizumab containing arm feasible in patients with recurrent cervical cancer?
authors: Division of Gynecologic Oncology, University of California, Irvine School of Medicine, Orange, CA, USA. Electronic address: lauren.krill@uci.edu.
authors: Lauren S
authors: LS
authors: Krill
authors: Institute for Health & Aging, University of California, San Francisco, CA 94118, USA. Electronic address: joel.adelson@ucsf.edu.
authors: Joel W
authors: JW
authors: Adelson
authors: Division of Gynecologic Oncology, University of California, Irvine School of Medicine, Orange, CA, USA.
authors: Leslie M
authors: LM
authors: Randall
authors: Division of Gynecologic Oncology, University of California, Irvine School of Medicine, Orange, CA, USA. Electronic address: rbristow@uci.edu.
authors: Robert E
authors: RE
authors: Bristow
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D026688:Bioethical Issues; D035843:Biomedical Research / Q000941:ethics*; D002986:Clinical Trials as Topic / Q000941:ethics*; D004992:Ethics, Medical; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D013739:Testosterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D013739:Testosterone; C001371:boldenone undecylenate